Response to firstline (1L) pembrolizumab (pembro) plus chemotherapy (chemo) in nonsmall cell lung cancer (NSCLC) by blood tumor mutational burden (bTMB): the phase 2 KEYNOTE-782 trialJair Bar,Emilio Esteban,Delvys Rodriguez-Abreu,Santiago Ponce Aix,Zsuzsanna Szalai,Enriqueta Felip,Maya Gottfried, Mariano Provencio Pulla,Andrew Robinson,Andrea Fulop,Suman B. Rao,D. Ross Camidge,Giovanna Speranza, Steven M. Townson, Julie Kobie,Mark Ayers, Elisha J. Dettman, Robert McDaniel, Byoungsok Jung, David Burkhardt, Ruth Mauntz,Tibor CsosziCANCER RESEARCH（2023）引用 0|浏览16暂无评分AI 理解论文溯源树样例生成溯源树，研究论文发展脉络Chat Paper正在生成论文摘要
